News | May 07, 2026
Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum
The standout story remains Wegovy, particularly its new oral formulation
The standout story remains Wegovy, particularly its new oral formulation
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
The approval introduces a needle-free alternative to injectable GLP-1 therapies
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Subscribe To Our Newsletter & Stay Updated
